Updated results of a phase 1, first-in-human study of talquetamab, a G protein-coupled receptor family C group 5 member D (GPRC5D) x CD3 bispecific antibody, in relapsed/refractory multiple myeloma (MM).
Por:
Berdeja, JG, Krishnan, AY, Oriol, A, van de Donk, NWCJ, Rodriguez-Otero, P, Askari, E, Mateos, MV, Minnema, MC, Costa, LJ, Verona, R, Girgis, S, Prior, T, Hilder, B, Russell, JS, Goldberg, JD and Chari, A
Publicada:
20 may 2021
Resumen:
Filiaciones:
Sarah Cannon Res Inst, Nashville, TN USA.
Tennessee Oncol, Nashville, TN USA.
City Hope Natl Med Ctr, Comprehens Canc Ctr, Duarte, CA USA.
Hosp Badalona Germans Trias & Pujol, Inst Catala Oncol, Barcelona, Spain.
Hosp Badalona Germans Trias & Pujol, Inst Josep Carreras, Barcelona, Spain.
Vrije Univ Amsterdam, Amsterdam Univ, Med Ctr, Amsterdam, Netherlands.
Clin Univ Navarra, Navarra, Spain.
Hosp Univ Fdn Jimenez Diaz, Madrid, Spain.
Hosp Clin Univ Salamanca, Salamanca, Spain.
Univ Med Ctr Utrecht, Utrecht, Netherlands.
Univ Alabama Birmingham, Birmingham, AL USA.
Janssen R&D, Spring House, PA USA.
Janssen R&D, Raritan, NJ USA.
Mt Sinai Sch Med, New York, NY USA.
|